The partnership with Aitia is likely to be viewed positively by investors as it represents an investment in innovative technology that could streamline the drug discovery process, leading to potential cost savings and faster time-to-market for new drugs. This could give CRL a competitive edge in the contract research organization (CRO) industry, particularly in the high-stakes fields of neurodegenerative diseases and oncology.